Recombinant adeno-associated virus capsids resistant to pre-existing human neutralizing antibodies
US10532111B2 · kind B2 · utility
15Cited by
0References
50Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 18, 2017 |
| Grant date | Jan 14, 2020 |
| Priority date | — |
| Expiry date | Aug 18, 2037 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2469/20
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to variant AAV capsid polypeptides, wherein the variant capsid polypeptides exhibit an enhanced neutralization profile, increased transduction and/or tropism in human liver tissue or hepatocyte cells (i.e., human hepatocyte cells), or both, as compared non-variant parent capsid polypeptides.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.